Ocular Therapeutix (OCUL) Misses Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
BTIG Downgrades Ocular Therapeutix (OCUL) to Neutral
May 5, 2017 2:35 PM EDTBTIG downgraded Ocular Therapeutix (NASDAQ: OCUL) from Buy to Neutral. Analyst Dane Leone thinks there is risk of a delay in the current PDUFA date for Dextenza.
For an analyst ratings summary and ratings history on Ocular Therapeutix... More
